{"id":"NCT02987543","sponsor":"AstraZeneca","briefTitle":"Study of Olaparib (Lynparza™) Versus Enzalutamide or Abiraterone Acetate in Men With Metastatic Castration-Resistant Prostate Cancer (PROfound Study)","officialTitle":"A Phase III, Open Label, Randomized Study to Assess the Efficacy and Safety of Olaparib (Lynparza™) Versus Enzalutamide or Abiraterone Acetate in Men With Metastatic Castration-Resistant Prostate Cancer Who Have Failed Prior Treatment With a New Hormonal Agent and Have Homologous Recombination Repair Gene Mutations (PROfound)","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2017-02-06","primaryCompletion":"2019-06-04","completion":"2023-02-15","firstPosted":"2016-12-09","resultsPosted":"2020-10-12","lastUpdate":"2023-10-06"},"enrollment":387,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Metastatic Castration-resistant Prostate Cancer"],"interventions":[{"type":"DRUG","name":"olaparib","otherNames":["Lynparza"]},{"type":"DRUG","name":"enzalutamide","otherNames":["XTANDI"]},{"type":"DRUG","name":"abiraterone acetate","otherNames":["ZYTIGA"]},{"type":"DRUG","name":"abiraterone acetate","otherNames":["ZYTIGA"]},{"type":"DRUG","name":"enzalutamide","otherNames":["XTANDI"]}],"arms":[{"label":"Olaparib","type":"EXPERIMENTAL"},{"label":"Enzalutamide OR abiraterone acetate","type":"ACTIVE_COMPARATOR"}],"summary":"The purpose of this study is to evaluate the efficacy and safety of olaparib versus enzalutamide or abiraterone acetate in subjects with metastatic castration-resistant prostate cancer who have failed prior treatment with a new hormonal agent and have homologous recombination repair gene mutations.","primaryOutcome":{"measure":"Radiological Progression Free Survival (rPFS) by Blinded Independent Central Review (BICR) - Cohort A Only","timeFrame":"Tumor assessments every 8 weeks from randomisation until radiographic progression assessed by BICR (median duration of treatment of 7 and 4 months for Olaparib and Investigators Choice of NHA respectively).","effectByArm":[{"arm":"Cohort A Olaparib 300mg bd","deltaMin":7.39,"sd":null},{"arm":"Cohort A Investigators Choice of NHA","deltaMin":3.55,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"<0.0001"}]},"eligibility":{"minAge":"18 Years","sex":"MALE","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":204,"countries":["United States","Argentina","Australia","Austria","Brazil","Canada","Denmark","France","Germany","Israel","Italy","Japan","Netherlands","Norway","South Korea","Spain","Sweden","Taiwan","Turkey (Türkiye)","United Kingdom"]},"refs":{"pmids":["37963304","35598359","35229141","35157830","35091440","32955174","32343890"],"seeAlso":["https://filehosting-v2.pharmacm.com/api/Attachment/Download?tenantId=80217111&amp;parentIdentifier=D081DC00007&amp;attachmentIdentifier=fe1712ee-5e58-4f7d-a072-3044f698908d&amp;fileName=D081DC00007_CSP_redacted.pdf&amp;versionIdentifier=","https://filehosting-v2.pharmacm.com/api/Attachment/Download?tenantId=80217111&amp;parentIdentifier=D081DC00007&amp;attachmentIdentifier=441f6e9d-6f12-410a-9352-dca653de8d9c&amp;fileName=D081DC00007_SAP_redacted.pdf&amp;versionIdentifier=","https://filehosting-v2.pharmacm.com/api/Attachment/Download?tenantId=80217111&amp;parentIdentifier=D081DC00007&amp;attachmentIdentifier=cedcfc75-9a55-4974-b756-654ad809ea1b&amp;fileName=d081dc00007-addendum-2-study-synopsis_Redacted.pdf&amp;versionIdentifier="]},"adverseEventsSummary":{"seriousAny":{"events":94,"n":256},"commonTop":["Nausea","Anaemia","Decreased appetite","Fatigue","Constipation"]}}